Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung identifies BIRC5 as a putative target for therapy

ABSTRACT: Patients undergoing surgery for squamous cell carcinomas of the lung were included, a total of 188 tumours and 21 matched normal lung tissue. mRNA gene expression was analysed using Agilent gene expression arrays. Biological subtypes were explored.

ORGANISM(S): Homo sapiens

SUBMITTER: Vilde Haakensen 

PROVIDER: E-MTAB-8615 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml

Similar Datasets

Unknown Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy.
| S-EPMC7540694 | biostudies-literature
Unknown Clinicopathologic and Genomic Analysis of <i>TP53</i>-Mutated Endometrial Carcinomas.
| S-EPMC8530276 | biostudies-literature
Unknown The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
| S-EPMC6433262 | biostudies-literature
Unknown Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas.
| S-EPMC7370910 | biostudies-literature
Unknown Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome - not because we can, but because we should.
| S-EPMC5709095 | biostudies-literature
Unknown TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy.
| S-EPMC8151854 | biostudies-literature
Unknown Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
| S-EPMC7013259 | biostudies-literature
Unknown MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies.
| S-EPMC4679059 | biostudies-literature
Unknown TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes.
| S-EPMC8582962 | biostudies-literature
Other Ataxia-telangiectasia mutated (Atm) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy
2023-11-04 | GSE246584 | GEO